Breakthroughs in Blood Cancer treatments I latest Advancements and innovations in Blood Cancer

Breakthrough in Blood Cancer Treatments

The Advances in diagnosing and treating blood cancers have helped double survival rates. Hence, the future outlook may be even brighter with treating Blood Cancer.

Blood cancers (Leukemia, Lymphoma and Myeloma) are made up almost 10% of all cancer cases diagnosed in 2015, or about 162,000 new cancer cases.

At the same time, progress is being made on the survival front.
More than 1 million people are either living with the disease or are survivors.

LYMPHOMA:
The most common type of blood cancer, with more than 80,000 cases diagnosed each year, lymphoma starts in the cells of the body’s immune system. There are two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
The 5-year survival rate for both cancers has more than doubled during the past 50 years. HL is typically treated with chemotherapy and radiation, while NHL treatments may include stem cell therapy and drugs known as monoclonal antibodies.

Breakthrough: The FDA approved ibrutinib in 2013 as a treatment for patients with a particularly aggressive form of NHL known as mantle cell lymphoma. The drug is also being studied to determine whether it may help fight another type of NHL, follicular lymphoma, and the results are promising.

LEUKEMIA:
This typically affects the WBCs, but it can also occur in RBCs & in platelets. Leukemia is classified as acute (fast growing) & chronic (slow growing). There are 4 main types: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
The five-year relative survival rate for leukemia has more than doubled during the past 50 years.
Depending on the type of leukemia, treatment options include stem cell transplants, chemotherapy, radiation therapy and immunotherapy.

Breakthrough: AML is considered one of the deadliest types of leukemia, with a 5-year survival rate just over 25%. Researchers are now studying an experimental drug that inhibits the activity of FLT3, a gene mutation linked to this disease. Early results are quite promising.

MYELOMA:
This cancer is caused by malignant plasma cells, which are found in the bone marrow & t’s the least common of the three cancers. The 5-year relative survival rates have increased from 12% to 46.7 % in the past 50 years which can greatly improve quality of life.

Awareness is the key....

Consult with the renowned Hematologist Dr. Rahul Bhargava.

DR. RAHUL BHARGAVA
MBBS, MD (Medicine), DM (Clinical Hematology)
Director of Hematology, Pediatric Hematology & Bone Marrow Transplant Unit
FORTIS MEMORIAL HOSPITAL, GURUGRAM

Specialty:- Aplastic Anemia l Leukemia l Lymphoma l Multiple Myeloma l ITP

CANCER ROUNDS
[phone]
(24X7 helpline for Cancer patients)

#BloodCancerAwarenessMonth
#cancerpatients #cancerrounds #cancerOPD #DrPriyaTiwari #Hematologist #aplasticanemia #leukemia #ITP #lymphoma #multiplemyeloma #cancerawareness #amenia #Bloodcancer #oncologist #Bonemarrowtransplant #bonemarrowtrasnplantation #Cancertreatements #cancertherapies #medicaloncologist

[rachnaverma]

It's quite knowledgeable and good in terms of awareness should be aware cancer's signs n symptoms.